Advanced search
Publication Cover
Expert Opinion on Drug Metabolism & Toxicology Volume 19, 2023 - Issue 6
Submit an article Journal homepage
1,148
Views
1
CrossRef citations to date
0
Altmetric
Editorial

The impact of COVID-19 infection on cytochrome P450 3A4-mediated drug metabolism and drug interactions

Samuel Villemurea College of Pharmacy, Dalhousie University, Halifax, Nova Scotia, CanadaView further author information
,
Shanna C Trenamana College of Pharmacy, Dalhousie University, Halifax, Nova Scotia, Canada;b Nova Scotia Health Authority, Halifax, Nova ScotiaView further author information
&
Kerry B Goralskia College of Pharmacy, Dalhousie University, Halifax, Nova Scotia, Canada;c Department of Pharmacology, Dalhousie University, Halifax, Nova Scotia, Canada;d Department of Pediatrics, IWK Health Centre;e Beatrice Hunter Cancer Research Institute, Halifax, Nova Scotia, CanadaCorrespondence[email protected]
View further author information
Pages 329-332 | Received 12 Apr 2023, Accepted 20 Jun 2023, Published online: 26 Jun 2023

References

  • Johns Hopkins University of Medicine. COVID-19 dashboard 2023. [cited 2023 Mar 30]. Available from: https://coronavirus.jhu.edu/map.html
  • Garcia LF. Immune response, inflammation, and the clinical spectrum of COVID-19. Front Immunol. 2020;11:1441. doi: 10.3389/fimmu.2020.01441
  • Kraemer MJ, Furukawa CT, Koup JR, et al. Altered theophylline clearance during an influenza B outbreak. Pediatrics. 1982 Apr;69(4):476–480. doi: 10.1542/peds.69.4.476.
  • Lenoir C, Terrier J, Gloor Y, et al. Impact of SARS-CoV-2 infection (COVID-19) on cytochromes P450 activity assessed by the Geneva cocktail. Clin Pharmacol Ther. 2021 Nov;110(5):1358–1367. doi: 10.1002/cpt.2412.
  • McColl ER, Croyle MA, Zamboni WC, et al. COVID-19 vaccines and the virus: impact on drug metabolism and pharmacokinetics. Drug Metab Dispos. 2023 Jan;51(1):130–141. doi: 10.1124/dmd.122.000934.
  • Burk O, Wojnowski L. Cytochrome P450 3A and their regulation. Naunyn Schmiedebergs Arch Pharmacol. 2004 Jan;369(1):105–124. doi: 10.1007/s00210-003-0815-3
  • Gallo P, De Vincentis A, Pedone C, et al. Drug-drug interactions involving CYP3A4 and p-glycoprotein in hospitalized elderly patients. Eur J Intern Med. 2019 Jul;65:51–57.
  • Hakkola J, Hukkanen J, Turpeinen M, et al. Inhibition and induction of CYP enzymes in humans: an update. Arch Toxicol. 2020 Nov;94(11):3671–3722. doi: 10.1007/s00204-020-02936-7.
  • Marzolini C, Stader F, Stoeckle M, et al. Effect of systemic inflammatory response to SARS-CoV-2 on lopinavir and hydroxychloroquine plasma concentrations. Antimicrob Agents Chemother. 2020 Aug 20;64(9). doi: 10.1128/AAC.01177-20
  • Stader F, Battegay M, Sendi P, et al. Physiologically based pharmacokinetic modelling to investigate the impact of the cytokine storm on CYP3A drug pharmacokinetics in COVID-19 patients. Clin Pharmacol Ther. 2022 Mar;111(3):579–584.
  • Rasool SO, Nahr AM, Eskandari S, et al. Drug-disease interactions of differentially expressed genes in COVID-19 liver samples: an in-silico analysis. Investigacion Clinica. 2021;62(4):316–324. doi:10.22209/IC.v62n4a03
  • Smeets TJL, Valkenburg AJ, van der Jagt M, et al. Hyperinflammation Reduces midazolam metabolism in critically Ill adults with COVID-19. Clin Pharmacokinet. 2022 Jul;61(7):973–983.
  • Le Carpentier EC, Canet E, Masson D, et al. Impact of inflammation on midazolam metabolism in severe COVID-19 patients. Clin Pharmacol Ther. 2022 Nov;112(5):1033–1039.
  • Heagler K, Tejani K, Sanchez S. Impact of Covid-19 infection on tacrolimus levels in solid organ transplant recipients. Am J Transplant. 2021;21(S4): 861.
  • Bajpai D, Saxena N, Gandhi C, et al. Does COVID-19 increase tacrolimus levels in kidney transplant recipients? J Clin Pharm Ther. 2022 May;47(5):707–708.
  • Troy S. Serious adverse reactions due to DDIs in New Drug Application (NDA) 217188 Paxlovid (nirmatrelvir tablets; ritonavir tablets), co-packaged. Treatment of mild-to-moderate COVID-19 in adults who are at high risk for progrssion to severe COVID-19, including hospitalization and death, Antimicrobial Drugs Advisory Committee Meeting, March 16, 2023. 2023 29 May. 2023. https://www.fda.gov/media/166237/download
  • Bihan K, Lipszyc L, Lemaitre F, et al. Nirmatrelvir/Ritonavir (Paxlovid(r)): French pharmacovigilance survey 2022. Therapie. 2023 Mar 7. doi: 10.1016/j.therap.2023.03.001
  • Sathe AG, Othman AA, Mohamed MF. Therapeutic protein drug interaction potential in subjects with psoriasis: an assessment based on population pharmacokinetic analyses of sensitive cytochrome P450 probe substrates. J Clin Pharmacol. 2021 Mar;61(3):307–318. doi: 10.1002/jcph.1744
  • US Food & Drug Administration. Drug development and drug interactions | Table of Substrates, inhibitors and inducers web page2022. [cited 2023 Apr 11]. https://www.fda.gov/drugs/drug-interactions-labeling/drug-development-and-drug-interactions-table-substrates-inhibitors-and-inducers

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.